Beyond cytokines, chemokines, and sICs, soluble CD14 (sCD14) and soluble CD163 (sCD163) as myeloid differentiation and activation markers are elevated in the plasma of COVID-19 patients and associated with immunopathology (24). Here, CD163 is linked to COVID-19.